newsfilter
← Latest News
GlobeNewswire·

Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson's Disease Drug Candidate

Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson's Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe